Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Abstract

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).

Keywords

MeSH Terms

Affiliated Institutions

• KU Leuven BE
• UCSF Helen Diller Family Comprehensive Cancer Center US
• The Netherlands Cancer Institute NL
• Jagiellonian University PL
• Duke Cancer Institute
• Integrated Oncology (United States) US
• Sidney Kimmel Comprehensive Cancer Center US
• The University of Texas MD Anderson Cancer Center US
• University Hospital Cologne DE
• Florida Cancer Specialists & Research Institute US
• Princess Margaret Cancer Centre CA
• Ghent University Hospital BE
• John Paul II Hospital PL
• Heinrich Heine University Düsseldorf DE
• Université de Rennes FR
• Baylor University Medical Center US
• Universitair Ziekenhuis Leuven BE
• Inserm FR
• Düsseldorf University Hospital DE
• Bristol-Myers Squibb (United States) US
• University Medical Center of the Johannes Gutenberg University Mainz DE
• Duke Medical Center US
• Queen Elizabeth II Health Sciences Centre CA
• Akita University Hospital JP
• Hôpital Claude Huriez FR
• Johannes Gutenberg University Mainz DE
• Dana-Farber Cancer Institute US
• Johns Hopkins University US
• University of California, San Francisco US
• St John of God Murdoch Hospital AU

Related Publications